- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, June 10, 2022
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
The CER Daily Newsfeed, a newsletter from the National Pharmaceutical Council (NPC), cited a story on AJMC.com, the website of The American Journal of Managed Care® (AJMC®), about the Federal Trade Commission opening up an investigation into the business practices of the 6 largest pharmacy benefit managers. The story, "In Reversal, FTC Launches Inquiry Into PBM Industry," included interviews with the CEOs of the NPC as well as the Pontchartrain Cancer Center.
A piece by AJMC®'s sister site, Pharmacy Times®, cited a supplemental study published in AJMC®. The study, “Health Outcomes From an Innovative Enhanced Medication Therapy Management Model,” found that medication safety reviews were effective at improving annual health care costs, hospitalizations, emergency department visits, and mortality in Medicare beneficiaries targeted according to MedWise Risk Score.
ERISA Industry Committee Sues Minnesota Over PBM Law
January 3rd 2025The Employee Retirement Income Security Act (ERISA) Industry Committee filed a legal challenge against the Minnesota Department of Commerce, arguing that Minnesota’s Pharmacy Benefit Manager (PBM) Licensure and Regulation Act illegally interfered with employer-sponsored health plans by restricting plan design options and increasing costs.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
